Yuri A. Lykov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuri A. Lykov has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Zhanna Yu. Chefranova
Belgorod State National Research University
7 shared publications - Ol'Ga A. Osipova
Belgorod State National Research University
6 shared publications - Elena Vladimirovna Gosteva
Voronezh State Medical Academy named after N.N. Burdenko, Russian Ministry of Health
5 shared publications - Sergey S. Markin
Institute of Biomedical Chemistry
4 shared publications - Andrey M. Semenov
Faculty of Economics, Patrice Lumumba Peoples’ Friendship University of Russia (RUDN), Moscow (A.M.S., M.P.S.).
3 shared publications - E. A. Ponomarev
City Clinical Emergency Hospital No. 25. 2. Volgograd State Medical University
3 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by National Medical Research Center For Rehabilitation And Balneology in Bulletin of Rehabilitation Medicine
- Vol. 25 (2) , 63-76
Heart rate variability in stress assessment and autonomic regulation: current state of the art, clinical applications and outlook. A literature Review
INTRODUCTION. Heart rate variability (HRV) is a noninvasive physiological marker reflecting autonomic regulation and the balance between sympathetic and parasympathetic influences. HRV is increasingly being used to assess acute and chronic stress, as well as in the diagnosis of anxiety and depressive disorders, suicidal risk and for some neurological diseases. AIM. To analyze modern ideas about HRV as an objective marker of stressful conditions and autonomous regulation, evaluate its diagnostic capabilities for mental and neurological disorders, as well as identify methodological limitations and prospects for clinical application. MATERIALS AND METHODS. A literature review was conducted using PubMed, Medline, Scopus, Web of Science and eLIBRARY.RU databases, covering publications from 2015 to 2025. The search terms that were used included heart rate variability, HRV, stress, autonomic nervous system, anxiety, depression, suicidal behavior, neurological diseases, and wearable devices. MAIN CONTENT OF THE REVIEW. Data on physiological mechanisms of HRV formation, recording techniques, and analysis of time-domain, frequency-domain, and nonlinear parameters were summarized. The most reproducible feature of stress-related dysregulation is reduced indices reflecting vagal modulation of heart rate. Decreased HRV has been observed in individuals with anxiety and depressive disorders, suicidal tendencies, epilepsy, Parkinson’s disease, traumatic brain injury and other neurological conditions. It is also associated with an adverse prognosis. However, HRV is not a specific marker of sympathetic activity or stress level and is strongly influenced by recording conditions, respiration, age, medication, and comorbidity. CONCLUSION. HRV is an informative indicator of autonomic regulation and stress-related alterations; however, its clinical interpretation requires consideration of methodological constraints and integration into comprehensive, personalized assessment models.
- 23 April 2026
- Published by National Medical Research Center For Rehabilitation And Balneology in Bulletin of Rehabilitation Medicine
- Vol. 25 (2) , 63-76
Open AccessHeart rate variability in stress assessment and autonomic regulation: current state of the art, clinical applications and outlook. A literature Review
INTRODUCTION. Heart rate variability (HRV) is a noninvasive physiological marker reflecting autonomic regulation and the balance between sympathetic and parasympathetic influences. HRV is increasingly being used to assess acute and chronic stress, as well as in the diagnosis of anxiety and depressive disorders, suicidal risk and for some neurological diseases. AIM. To analyze modern ideas about HRV as an objective marker of stressful conditions and autonomous regulation, evaluate its diagnostic capabilities for mental and neurological disorders, as well as identify methodological limitations and prospects for clinical application. MATERIALS AND METHODS. A literature review was conducted using PubMed, Medline, Scopus, Web of Science and eLIBRARY.RU databases, covering publications from 2015 to 2025. The search terms that were used included heart rate variability, HRV, stress, autonomic nervous system, anxiety, depression, suicidal behavior, neurological diseases, and wearable devices. MAIN CONTENT OF THE REVIEW. Data on physiological mechanisms of HRV formation, recording techniques, and analysis of time-domain, frequency-domain, and nonlinear parameters were summarized. The most reproducible feature of stress-related dysregulation is reduced indices reflecting vagal modulation of heart rate. Decreased HRV has been observed in individuals with anxiety and depressive disorders, suicidal tendencies, epilepsy, Parkinson’s disease, traumatic brain injury and other neurological conditions. It is also associated with an adverse prognosis. However, HRV is not a specific marker of sympathetic activity or stress level and is strongly influenced by recording conditions, respiration, age, medication, and comorbidity. CONCLUSION. HRV is an informative indicator of autonomic regulation and stress-related alterations; however, its clinical interpretation requires consideration of methodological constraints and integration into comprehensive, personalized assessment models.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 43-59
Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry
Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 43-59
Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry
Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.
- Open Access
- 29 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (5) , 415-428
Study of the pharmacokinetics of non-immunogenic staphylokinase in patients with acute myocardial infarction and acute ischemic stroke
The aim. To investigate the pharmacokinetic parameters of non-immunogenic staphylokinase (Fortelyzin®, SuperGene LLC, Russia) in patients with acute myocardial infarction with ST-segment elevation (STEMI) on the electrocardiogram and in patients with ischemic stroke.Materials and methods. The clinical study was conducted in 50 patients with STEMI after a single intravenous administration of non-immunogenic staphylokinase at a dose of 15 mg and in 50 patients with ischemic stroke after a single intravenous administration of the drug at a dose of 10 mg. The main pharmacokinetic parameters were determined: half-life, initial concentration, volume of distribution, clearance, and area under the pharmacokinetic curve.Results. As a result of the study of the pharmacokinetics of non-immunogenic staphylokinase, it was found that after a single intravenous administration of the drug at a dose of 15 mg, the initial concentration was 7.1 ± 2.7 μg/mL, the half-life was 5.77 ± 0.72 min, the clearance was 0.33 ± 0.04 l/min, and the area under the pharmacokinetic curve (AUC0-t) was 42.9 ± 3.2 μg/mL*min. After administration of the drug at a dose of 10 mg, the initial concentration was 2.8 ± 0.3 μg/ml, the half-life was 5.11 ± 0.56 min, the clearance was 0.35 ± 0.06 l/min, and the area under the pharmacokinetic curve (AUC0-t) was 28.5 ± 3.6 μg/mL*min. The terminal half-life was 32 min in both dosage regimens.Conclusion. It was found that non-immunogenic staphylokinase is characterized by a short half-life and high clearance, which ensures the safety of the drug in clinical practice. The peculiarities of the pharmacodynamics of non-immunogenic staphylokinase, associated with its interaction with plasmin in the thrombus and subsequent recirculation of released drug molecules, allow it to be used in low doses, regardless of the patient’s body weight, despite the short half-life.
- 29 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (5) , 415-428
Open AccessStudy of the pharmacokinetics of non-immunogenic staphylokinase in patients with acute myocardial infarction and acute ischemic stroke
The aim. To investigate the pharmacokinetic parameters of non-immunogenic staphylokinase (Fortelyzin®, SuperGene LLC, Russia) in patients with acute myocardial infarction with ST-segment elevation (STEMI) on the electrocardiogram and in patients with ischemic stroke.Materials and methods. The clinical study was conducted in 50 patients with STEMI after a single intravenous administration of non-immunogenic staphylokinase at a dose of 15 mg and in 50 patients with ischemic stroke after a single intravenous administration of the drug at a dose of 10 mg. The main pharmacokinetic parameters were determined: half-life, initial concentration, volume of distribution, clearance, and area under the pharmacokinetic curve.Results. As a result of the study of the pharmacokinetics of non-immunogenic staphylokinase, it was found that after a single intravenous administration of the drug at a dose of 15 mg, the initial concentration was 7.1 ± 2.7 μg/mL, the half-life was 5.77 ± 0.72 min, the clearance was 0.33 ± 0.04 l/min, and the area under the pharmacokinetic curve (AUC0-t) was 42.9 ± 3.2 μg/mL*min. After administration of the drug at a dose of 10 mg, the initial concentration was 2.8 ± 0.3 μg/ml, the half-life was 5.11 ± 0.56 min, the clearance was 0.35 ± 0.06 l/min, and the area under the pharmacokinetic curve (AUC0-t) was 28.5 ± 3.6 μg/mL*min. The terminal half-life was 32 min in both dosage regimens.Conclusion. It was found that non-immunogenic staphylokinase is characterized by a short half-life and high clearance, which ensures the safety of the drug in clinical practice. The peculiarities of the pharmacodynamics of non-immunogenic staphylokinase, associated with its interaction with plasmin in the thrombus and subsequent recirculation of released drug molecules, allow it to be used in low doses, regardless of the patient’s body weight, despite the short half-life.
- Open Access
- 23 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6157
Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.
- 23 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6157
Open AccessNon-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.
- 3 October 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (9)
Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
Aim . To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS). Material and methods . 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were examined. Patients were randomly divided into pharmacotherapy groups: 47 patients took telmisartan (80 mg/day) and 45 — perindopril (10 mg/day). Fasting plasma glucose levels, insulin, leptin, total cholesterol, triglycerides, highand lowdensity lipoprotein cholesterol were determined, the HOMA-IR index was calculated, and daily monitoring was performed. Statistical processing was carried out using STATISTICA 10,0. The indicators are presented in the form of the median, interquartile ranges of Me (Q25%; Q75%), and mean ±SD. The comparison was carried out using the Wilcoxon rank criterion. The differences are significant at pResults . After 12 months of observation in the telmisartan group, there was a significant decrease in the average daily systolic blood pressure (ВРs) from 152 (146; 156) to 129 (125; 134) mm Hg (pConclusion . Elderly patients with hypertension on the background of MS and a history of IS had significantly decreased ВРs and ВРd (according to the results of daily monitoring) after 12 months of telmisartan pharmacotherapy, decreased insulin resistance and the level of leptin and triglycerides in the blood serum.
- 3 October 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (9)
Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
Aim . To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS). Material and methods . 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were examined. Patients were randomly divided into pharmacotherapy groups: 47 patients took telmisartan (80 mg/day) and 45 — perindopril (10 mg/day). Fasting plasma glucose levels, insulin, leptin, total cholesterol, triglycerides, highand lowdensity lipoprotein cholesterol were determined, the HOMA-IR index was calculated, and daily monitoring was performed. Statistical processing was carried out using STATISTICA 10,0. The indicators are presented in the form of the median, interquartile ranges of Me (Q25%; Q75%), and mean ±SD. The comparison was carried out using the Wilcoxon rank criterion. The differences are significant at pResults . After 12 months of observation in the telmisartan group, there was a significant decrease in the average daily systolic blood pressure (ВРs) from 152 (146; 156) to 129 (125; 134) mm Hg (pConclusion . Elderly patients with hypertension on the background of MS and a history of IS had significantly decreased ВРs and ВРd (according to the results of daily monitoring) after 12 months of telmisartan pharmacotherapy, decreased insulin resistance and the level of leptin and triglycerides in the blood serum.
- Open Access
- 3 October 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (9) , 3390
Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
Aim. To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS).Material and methods. 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were examined. Patients were randomly divided into pharmacotherapy groups: 47 patients took telmisartan (80 mg/day) and 45 — perindopril (10 mg/day). Fasting plasma glucose levels, insulin, leptin, total cholesterol, triglycerides, highand lowdensity lipoprotein cholesterol were determined, the HOMA-IR index was calculated, and daily monitoring was performed. Statistical processing was carried out using STATISTICA 10,0. The indicators are presented in the form of the median, interquartile ranges of Me (Q25%; Q75%), and mean ±SD. The comparison was carried out using the Wilcoxon rank criterion. The differences are significant at pResults. After 12 months of observation in the telmisartan group, there was a significant decrease in the average daily systolic blood pressure (ВРs) from 152 (146; 156) to 129 (125; 134) mm Hg (pConclusion. Elderly patients with hypertension on the background of MS and a history of IS had significantly decreased ВРs and ВРd (according to the results of daily monitoring) after 12 months of telmisartan pharmacotherapy, decreased insulin resistance and the level of leptin and triglycerides in the blood serum.
- 3 October 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (9) , 3390
Open AccessAdvantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
Aim. To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS).Material and methods. 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were examined. Patients were randomly divided into pharmacotherapy groups: 47 patients took telmisartan (80 mg/day) and 45 — perindopril (10 mg/day). Fasting plasma glucose levels, insulin, leptin, total cholesterol, triglycerides, highand lowdensity lipoprotein cholesterol were determined, the HOMA-IR index was calculated, and daily monitoring was performed. Statistical processing was carried out using STATISTICA 10,0. The indicators are presented in the form of the median, interquartile ranges of Me (Q25%; Q75%), and mean ±SD. The comparison was carried out using the Wilcoxon rank criterion. The differences are significant at pResults. After 12 months of observation in the telmisartan group, there was a significant decrease in the average daily systolic blood pressure (ВРs) from 152 (146; 156) to 129 (125; 134) mm Hg (pConclusion. Elderly patients with hypertension on the background of MS and a history of IS had significantly decreased ВРs and ВРd (according to the results of daily monitoring) after 12 months of telmisartan pharmacotherapy, decreased insulin resistance and the level of leptin and triglycerides in the blood serum.
- Open Access
- 8 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (8) , 3087
Dynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke receiving beta-blockers
Aim. To compare the effect of beta-blocker therapy (bisoprolol and nebivolol) on the dynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke (IS).Material and methods. This prospective cohort study included 75 hypertensive patients who were admitted to the hospital due to IS. The mean age of patients was 67±6 years. The average National Institutes of Health Stroke Scale (NIHSS) score was 7±3. The followup period was 6 months. The control group consisted of 20 elderly people with hypertension without prior myocardial infarction. The patients were divided into groups based on received therapy: group 1 (n=38) — bisoprolol; group 2 (n=37) — nebivolol. The level of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) was determined by enzyme-linked immunosorbent assay (ELISAKit, USA). Vascular ultrasound was carried out using a LOGIQP9 (GE) system according to the Celermajer method.Results. After 6-month nebivolol, we revealed a decrease in the level of MMP-9 by 30,2% (pConclusion. The results obtained indicate that the beta-blocker nebivolol at an average dose of 8,55+1,75 mg/day significantly reduces the vascular fibrosis, normalizes the ratio of collagen synthesis and degradation markers, improves the vasodilation brachial artery properties in comparison with bisoprolol in elderly hypertensive patients after IS.
- 8 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (8) , 3087
Open AccessDynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke receiving beta-blockers
Aim. To compare the effect of beta-blocker therapy (bisoprolol and nebivolol) on the dynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke (IS).Material and methods. This prospective cohort study included 75 hypertensive patients who were admitted to the hospital due to IS. The mean age of patients was 67±6 years. The average National Institutes of Health Stroke Scale (NIHSS) score was 7±3. The followup period was 6 months. The control group consisted of 20 elderly people with hypertension without prior myocardial infarction. The patients were divided into groups based on received therapy: group 1 (n=38) — bisoprolol; group 2 (n=37) — nebivolol. The level of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) was determined by enzyme-linked immunosorbent assay (ELISAKit, USA). Vascular ultrasound was carried out using a LOGIQP9 (GE) system according to the Celermajer method.Results. After 6-month nebivolol, we revealed a decrease in the level of MMP-9 by 30,2% (pConclusion. The results obtained indicate that the beta-blocker nebivolol at an average dose of 8,55+1,75 mg/day significantly reduces the vascular fibrosis, normalizes the ratio of collagen synthesis and degradation markers, improves the vasodilation brachial artery properties in comparison with bisoprolol in elderly hypertensive patients after IS.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (7) , 56-65
Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение эффективности и безопасности неиммуногенной стафилокиназы (НС) в сравнении с алтеплазой (А) у пациентов с ишемическим инсультом (ИИ) в первые 4,5 ч от развития симптомов. МАТЕРИАЛ И МЕТОДЫ В открытом рандомизированном сравнительном исследовании «не меньшей эффективности» в параллельных группах НС и А приняли участие 336 пациентов (по 168 в каждой группе) в первые 4,5 ч ИИ. НС вводилась в дозе 10 мг вне зависимости от массы тела внутривенно болюсно в течение 10 с, А — болюсно-инфузионно в дозе 0,9 мг/кг (максимально 90 мг) в течение 1 ч. Первичной конечной точкой эффективности считался благоприятный исход — 0—1 балл по модифицированной шкале Рэнкина (mRS) на 90-й день после введения препаратов. Конечные точки безопасности включали смертность от всех причин на 90-й день, симптомное внутричерепное кровоизлияние и другие серьезные нежелательные явления (СНЯ). РЕЗУЛЬТАТЫ К 90-му дню заболевания первичную конечную точку в группе НС достигли 84 (50%) пациента, в группе А — 68 (41%) (p=0,10, ОШ=1,47, 95% ДИ=0,93—2,32). Разница между группами НС и А составила 9,5% (95% ДИ= –1,7—20,7), и левая граница 95% ДИ не пересекала границу «не меньшей эффективности» (p«не меньшей эффективности»p=0,32). Частота симптомных внутричерепных кровоизлияний была несколько реже в группе НС — 5 (3%) пациентов, в группе А — 13 (8%) (p=0,087, ОШ=0,37, 95% ДИ=0,1—1,13). СНЯ в группе НС развились у 22 (13%) пациентов, в группе А — у 37 (22%) (p=0,044, ОШ=0,53, 95% ДИ=0,28—0,98). ЗАКЛЮЧЕНИЕ Результаты исследования ФРИДА являются первыми в мире по применению препарата на основе НС у пациентов с ИИ. Показано, что однократное болюсное введение НС в стандартной дозе в 10 мг вне зависимости от массы тела позволяет быстро, эффективно и безопасно проводить тромболитическую терапию у пациентов с ИИ в течение 4,5 ч от начала заболевания. В дальнейших клинических исследованиях НС планируется расширение терапевтического окна в 4,5 ч после появления симптомов у пациентов с ИИ.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (7) , 56-65
Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение эффективности и безопасности неиммуногенной стафилокиназы (НС) в сравнении с алтеплазой (А) у пациентов с ишемическим инсультом (ИИ) в первые 4,5 ч от развития симптомов. МАТЕРИАЛ И МЕТОДЫ В открытом рандомизированном сравнительном исследовании «не меньшей эффективности» в параллельных группах НС и А приняли участие 336 пациентов (по 168 в каждой группе) в первые 4,5 ч ИИ. НС вводилась в дозе 10 мг вне зависимости от массы тела внутривенно болюсно в течение 10 с, А — болюсно-инфузионно в дозе 0,9 мг/кг (максимально 90 мг) в течение 1 ч. Первичной конечной точкой эффективности считался благоприятный исход — 0—1 балл по модифицированной шкале Рэнкина (mRS) на 90-й день после введения препаратов. Конечные точки безопасности включали смертность от всех причин на 90-й день, симптомное внутричерепное кровоизлияние и другие серьезные нежелательные явления (СНЯ). РЕЗУЛЬТАТЫ К 90-му дню заболевания первичную конечную точку в группе НС достигли 84 (50%) пациента, в группе А — 68 (41%) (p=0,10, ОШ=1,47, 95% ДИ=0,93—2,32). Разница между группами НС и А составила 9,5% (95% ДИ= –1,7—20,7), и левая граница 95% ДИ не пересекала границу «не меньшей эффективности» (p«не меньшей эффективности»p=0,32). Частота симптомных внутричерепных кровоизлияний была несколько реже в группе НС — 5 (3%) пациентов, в группе А — 13 (8%) (p=0,087, ОШ=0,37, 95% ДИ=0,1—1,13). СНЯ в группе НС развились у 22 (13%) пациентов, в группе А — у 37 (22%) (p=0,044, ОШ=0,53, 95% ДИ=0,28—0,98). ЗАКЛЮЧЕНИЕ Результаты исследования ФРИДА являются первыми в мире по применению препарата на основе НС у пациентов с ИИ. Показано, что однократное болюсное введение НС в стандартной дозе в 10 мг вне зависимости от массы тела позволяет быстро, эффективно и безопасно проводить тромболитическую терапию у пациентов с ИИ в течение 4,5 ч от начала заболевания. В дальнейших клинических исследованиях НС планируется расширение терапевтического окна в 4,5 ч после появления симптомов у пациентов с ИИ.
- Open Access
- 28 November 2021
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (7) , 3078
Effect of angiotensin II receptor blocker therapy on markers of fibrosis and immune inflammation in hypertensive patients with chronic kidney disease after ischemic stroke
Aim. To compare the effect of angiotensin II receptor blocker therapy (azilsartan, telmisartan) on fibrosis and immune inflammation markers in hypertensive patients with chronic kidney disease (CKD) after ischemic stroke (IS).Material and methods. The study included 76 hypertensive patients aged 60-74 years (mean age, 66±5 years) with CKD after IS. Patients were randomly divided into following pharmacotherapy groups: 38 patients — telmisartan group; 36 patients — azilsartan group. The control group consisted of 20 hypertensive people (mean age, 63±2 years) without a history of CKD and IS. The levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were determined by enzyme-linked immunosorbent assay (ELISA Kit, USA). The levels of interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), interferon γ (INF-γ), monocytic chemoattractant protein 1 (MCP-1) were assessed using Vector-Best kit (Russia).Results. Six-month azilsartan therapy led to a decrease in the levels of MMP-9 by 19,9% (pConclusion. Six-month telmisartan therapy in hypertensive patients with CKD after stroke was accompanied by a more pronounced decrease in markers of myocardial fibrosis (MMP-9, TIMP-1) and immune inflammation (TNF-α, INF-γ, MCP-1) compared with azilsartan, as well as with more pronounced improvement in renal function.
- 28 November 2021
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (7) , 3078
Open AccessEffect of angiotensin II receptor blocker therapy on markers of fibrosis and immune inflammation in hypertensive patients with chronic kidney disease after ischemic stroke
Aim. To compare the effect of angiotensin II receptor blocker therapy (azilsartan, telmisartan) on fibrosis and immune inflammation markers in hypertensive patients with chronic kidney disease (CKD) after ischemic stroke (IS).Material and methods. The study included 76 hypertensive patients aged 60-74 years (mean age, 66±5 years) with CKD after IS. Patients were randomly divided into following pharmacotherapy groups: 38 patients — telmisartan group; 36 patients — azilsartan group. The control group consisted of 20 hypertensive people (mean age, 63±2 years) without a history of CKD and IS. The levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were determined by enzyme-linked immunosorbent assay (ELISA Kit, USA). The levels of interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), interferon γ (INF-γ), monocytic chemoattractant protein 1 (MCP-1) were assessed using Vector-Best kit (Russia).Results. Six-month azilsartan therapy led to a decrease in the levels of MMP-9 by 19,9% (pConclusion. Six-month telmisartan therapy in hypertensive patients with CKD after stroke was accompanied by a more pronounced decrease in markers of myocardial fibrosis (MMP-9, TIMP-1) and immune inflammation (TNF-α, INF-γ, MCP-1) compared with azilsartan, as well as with more pronounced improvement in renal function.
- Open Access
- 14 November 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (5) , 2651
Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease
Влияние фармакотерапии на динамику маркеров обмена коллагена у больных хронической сердечной недостаточностью с промежуточной фракцией выброса на фоне ишемической болезни сердца в старших возрастных группах
- 14 November 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (5) , 2651
Open AccessEffect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease
Влияние фармакотерапии на динамику маркеров обмена коллагена у больных хронической сердечной недостаточностью с промежуточной фракцией выброса на фоне ишемической болезни сердца в старших возрастных группах